Cargando…

A Comparative Analysis of Individual RAS Mutations in Cancer Biology

In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode four highly homologous proteins. RAS proteins are small GTPases involved in a broad spectrum of key molecular and cellular activities, including proliferation and survival among others. Gain-of-function missense mut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muñoz-Maldonado, Carmen, Zimmer, Yitzhak, Medová, Michaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813200/ https://www.ncbi.nlm.nih.gov/pubmed/31681616 http://dx.doi.org/10.3389/fonc.2019.01088

Ejemplares similares

Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology
por: Zimmer, Yitzhak, et al.
Publicado: (2020)

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response — Biological and Clinical Aspects
por: Medová, Michaela, et al.
Publicado: (2013)

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
por: Poliaková, Michaela, et al.
Publicado: (2018)

Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer
por: Piguet, Anne-Christine, et al.
Publicado: (2015)

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
por: Nisa, Lluís, et al.
Publicado: (2017)

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
por: Hovhannisyan, Lusine, et al.
Publicado: (2023)

Profiling Invasiveness in Head and Neck Cancer: Recent Contributions of Genomic and Transcriptomic Approaches
por: Nisa, Lluís, et al.
Publicado: (2015)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis
por: Novoplansky, Ofra, et al.
Publicado: (2022)

Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review
por: Schanne, Daniel H., et al.
Publicado: (2022)

Leukemic conversion involving RAS mutations of type 1 CALR-mutated primary myelofibrosis in a patient treated for HCV cirrhosis: a case report
por: Gurban, Petruta, et al.
Publicado: (2023)

RAS as Supporting Actor in Breast Cancer
por: Galiè, Mirco
Publicado: (2019)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2020)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Mutations of RAS genes identified in acute myeloid leukemia affect glycerophospholipid metabolism pathway
por: Liang, Tianqi, et al.
Publicado: (2023)

Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology
por: Wang, Xiaojie, et al.
Publicado: (2021)

Ferroptosis: A Specific Vulnerability of RAS-Driven Cancers?
por: Andreani, Cristina, et al.
Publicado: (2022)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer
por: Maffeis, Valeria, et al.
Publicado: (2019)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

The Importance of microRNAs in RAS Oncogenic Activation in Human Cancer
por: Roncarati, Roberta, et al.
Publicado: (2019)

Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cells
por: Nita, Izabela, et al.
Publicado: (2017)

RAS: Striking at the Core of the Oncogenic Circuitry
por: Gimple, Ryan C., et al.
Publicado: (2019)

Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST
por: Astolfi, Annalisa, et al.
Publicado: (2020)

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
por: Damato, Angela, et al.
Publicado: (2021)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
por: Eleveld, Thomas F., et al.
Publicado: (2023)

Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs
por: Bosch-Guiteras, Núria, et al.
Publicado: (2021)

Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer
por: Guo, Jinxiu, et al.
Publicado: (2021)

Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity
por: Konstantinidou, Georgia, et al.
Publicado: (2020)

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

Liquid Biopsies in Progressing Metastatic Colorectal Cancer- Application and their Therapeutic Implications According to the RAS Status
por: Pereira, José, et al.
Publicado: (2020)

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
por: Lee, Shing Fung, et al.
Publicado: (2021)

Does Ras Activate Raf and PI3K Allosterically?
por: Nussinov, Ruth, et al.
Publicado: (2019)

Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury
por: Melin, Nicolas, et al.
Publicado: (2021)

RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
por: Miller, Mark Steven, et al.
Publicado: (2012)

An image-based modeling framework for predicting spatiotemporal brain cancer biology within individual patients
por: Bond, Kamila M., et al.
Publicado: (2023)

Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells
por: Gong, Jun, et al.
Publicado: (2014)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pfahiovf7qgvfn4sq73icf9gv1